Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2022 / Cilt: 56 - Sayı: 1

Relationship Between Thyroid-Stimulating Hormone Level and Aggressive Pathological Features of Papillary Thyroid Cancer

Pages
126–131
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

TSH level may be a pre-operative valuable predictive factor for patients’ risk of central metastasis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Thyroid-stimulating hormones (TSHs) are associated with the risk of differentiated thyroid cancer.
📊
Key Findings & Data:Methods: Patients who were operated between 2012 and 2017 and who were found to have PTC in their pathology were included in the study.
💡
Conclusion & Impact:TSH level may be a pre-operative valuable predictive factor for patients’ risk of central metastasis.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Thyroid-stimulating hormones (TSHs) are associated with the risk of differentiated thyroid cancer. The relationship between pre-operative TSH levels and aggressive features is unclear. We aimed to evaluate the relationship between pathological features of papillary thyroid carcinoma (PTC) and high TSH levels. Methods: Patients who were operated between 2012 and 2017 and who were found to have PTC in their pathology were included in the study. The relationship between TSH and the features of tumor aggressiveness was evaluated in the patients. Results: Of the 132 patients, TSH level was significantly higher in those with lymphovascular invasion than those without (p=0.048), in those with central metastases than in those without (p=0.014), and in those with extrathyroidal spread than in those without (p=0.003). When patients were categorized into four 25% quartiles according to TSH (mUI/mL) level; the rate of extrathyroidal invasion increased as the TSH level increased, and the level was significantly higher in quartile 1 than the others, with significant difference (p=0.030). Conclusion: Pre-operative increase in TSH level is associated with an increased risk of extrathyroidal spread and central lymph node metastasis. TSH level may be a pre-operative valuable predictive factor for patients’ risk of central metastasis.

🔖

Cite This Article

Unlu, M. T., Aygun, N., Demircioglu, M. K., Demircioglu, Z. G., Uludag, M., Kostek, M., Akgun, İ. E., Ozguven, M. B. Y. (2022). Relationship Between Thyroid-Stimulating Hormone Level and Aggressive Pathological Features of Papillary Thyroid Cancer. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 56 - Sayı: 1, 126–131. https://ajindex.com/articles/594615

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. . Carling T, Udelsman R. Thyroid cancer. Annu Rev Med 2014
  2. 125–37. 2. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrot-ropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012
  3. 2682–92. 3. Su A, Zhao W, Wu W, Wei T, Ruan M, Li Z, et al. The association of preoperative thy-roid-stimulating hormone level and the risk of differentiated thyroid cancer in patients with thyroid nodules: A systematic review and meta-analysis. Am J Surg 2020
  4. 634– 41. 4. Hu N, Li ZM, Liu JF, Zhang ZZ, Wang LS. An overall and dose-re- sponse meta-analysis for thyrotropin and thyroid cancer risk by histological type. Oncotarget 2016
  5. 47750–9. 5. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, et al. Thy-rotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mi-ce. Proc Natl Acad Sci U S A 2011
  6. 1615–20. 6. Biondi B, Cooper DS. Thyroid hormone suppression therapy. En- docrinol Metab Clin North Am 2019
  7. 227–37. 7. Besler E, Aygun N, Yetkin SG, Mihmanli M, Isgor A, Uludag M. The evaluation of the localisation and the extent of lympathic dissection in cen¬tral neck dissection. Sisli Etfal Hastan Tip Bul 2016
  8. 228–33. 8. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Niki- forov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differen- tiated thyroid cancer: The American Thyroid Association Guide- lines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016
  9. 1–133. 9. Besler E, Citgez B, Aygun N, Celayir MF, Ozguven MBY, Mihmanli M, et al. The rela-tionship of clinicopathological factors of the tumor with preoperative TSH level in papil-lary thyroid cancers. Eurasian J Med 2019
  10. 8–11. 10. Danilovic DL, Ferraz-de-Souza B, Fabri AW, Santana NO, Kulcsar MA, Cernea CR, et al. 25-Hydroxyvitamin D and TSH as risk fac- tors or prognostic markers in thyroid car-cinoma. PLoS One 2016
  11. e0164550. 11. LiVolsi VA. Papillary neoplasms of the thyroid. Pathologic and prognostic features. Am J Clin Pathol 1992
  12. 426–34. 12. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carci-noma. Thyroid 1999
  13. 421–7. 13. Kim SS, Lee BJ, Lee JC, Song SH, Kim BH, Son SM, et al. Preopera- tive serum thyroid stimulating hormone levels in well-differen- tiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis